Tokyo Tape
Sign in
← PeptiDream

Quarterly report · Q1

4587.TEDINET S100TFRV
Period2024-01-01 → 2024-03-31
Filed2024-05-15
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 48
MetricValuePeriodScopeSource row
Revenue¥4.2bn2024-01-01 → 2024-03-31Cons.Revenue IFRS
Revenue¥28.7bn2023-01-01 → 2023-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥5.0bn2023-01-01 → 2023-03-31Cons.Revenue IFRS
Operating income−¥1.1bn2024-01-01 → 2024-03-31Cons.Operating profit loss IFRS
Operating income−¥267m2023-01-01 → 2023-03-31Cons.Operating profit loss IFRS
Profit before tax−¥1.1bn2024-01-01 → 2024-03-31Cons.Profit loss before tax IFRS
Profit before tax¥4.4bn2023-01-01 → 2023-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax−¥400m2023-01-01 → 2023-03-31Cons.Profit loss before tax IFRS
Net income (owners)−¥843m2024-01-01 → 2024-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥3.0bn2023-01-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)−¥249m2023-01-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income−¥843m2024-01-01 → 2024-03-31Cons.Profit loss IFRS
Net income¥3.0bn2023-01-01 → 2023-12-31Cons.Profit loss IFRS (5-year summary)
Net income−¥249m2023-01-01 → 2023-03-31Cons.Profit loss IFRS
Total assets¥69.6bnat 2024-03-31Cons.Assets IFRS
Total assets¥69.5bnat 2023-12-31Cons.Assets IFRS
Total assets¥59.8bnat 2023-03-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥29.7bnat 2024-03-31Cons.Liabilities IFRS
Total liabilities¥29.1bnat 2023-12-31Cons.Liabilities IFRS
Net assets / equity¥40.0bnat 2024-03-31Cons.Equity IFRS
Net assets / equity¥40.3bnat 2023-12-31Cons.Equity IFRS
Net assets / equity¥31.8bnat 2023-03-31Cons.Equity IFRS
Net assets / equity¥32.0bnat 2022-12-31dCons.Equity IFRS
Equity (owners)¥40.0bnat 2024-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥40.3bnat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥31.8bnat 2023-03-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥27.3bnat 2024-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥19.5bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.6bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥5.2bnat 2022-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow−¥1.9bn2024-01-01 → 2024-03-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥12.4bn2023-01-01 → 2023-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥7.7bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow¥10.4bn2024-01-01 → 2024-03-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow¥1.3bn2023-01-01 → 2023-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥381m2023-01-01 → 2023-03-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥757m2024-01-01 → 2024-03-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥264m2023-01-01 → 2023-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥1.1bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-6.52024-01-01 → 2024-03-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥23.412023-01-01 → 2023-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥-1.922023-01-01 → 2023-03-31Cons.Basic earnings loss per share IFRS
EPS (diluted)¥-6.52024-01-01 → 2024-03-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥23.382023-01-01 → 2023-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥-1.922023-01-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS
Equity ratio57.4%at 2024-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio58.1%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio53.2%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-01-01 → 2024-03-31−¥75m
Reconciling Itemsreconcilingrevenue intersegment2024-01-01 → 2024-03-31−¥75m
jpcrp040300-q1r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2024-01-01 → 2024-03-31¥521m
jpcrp040300-q1r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2024-01-01 → 2024-03-31¥521m
jpcrp040300-q1r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2024-01-01 → 2024-03-31−¥955m
jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2024-01-01 → 2024-03-31¥3.8bn
jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2024-01-01 → 2024-03-31¥3.7bn
jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2024-01-01 → 2024-03-31¥75m
jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2024-01-01 → 2024-03-31−¥121m
—segment totalrevenue2024-01-01 → 2024-03-31¥4.3bn
—segment totalrevenue external2024-01-01 → 2024-03-31¥4.2bn
—segment totalrevenue intersegment2024-01-01 → 2024-03-31¥75m
—segment totalsegment profit2024-01-01 → 2024-03-31−¥1.1bn
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-03-31−¥3m
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-03-31−¥3m
jpcrp040300-q1r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2023-01-01 → 2023-03-31¥978m
jpcrp040300-q1r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2023-01-01 → 2023-03-31¥978m
jpcrp040300-q1r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2023-01-01 → 2023-03-31−¥381m
jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2023-01-01 → 2023-03-31¥4.0bn
jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2023-01-01 → 2023-03-31¥4.0bn
jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2023-01-01 → 2023-03-31¥3m
jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2023-01-01 → 2023-03-31¥136m
—segment totalrevenue2023-01-01 → 2023-03-31¥5.0bn
—segment totalrevenue external2023-01-01 → 2023-03-31¥5.0bn
—segment totalrevenue intersegment2023-01-01 → 2023-03-31¥3m
—segment totalsegment profit2023-01-01 → 2023-03-31−¥244m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 513
ItemContextValueUnit
Non current assets IFRSPrior1YearInstant42238930000JPY
Non current assets IFRSCurrentQuarterInstant34265519000JPY
Assets IFRSPrior1YearInstant69464013000JPY
Assets IFRSCurrentQuarterInstant69637141000JPY
Trade and other payables cl IFRSPrior1YearInstant3203559000JPY
Trade and other payables cl IFRSCurrentQuarterInstant3014164000JPY
Borrowings cl IFRSPrior1YearInstant2586259000JPY
Borrowings cl IFRSCurrentQuarterInstant2588019000JPY
Other financial liabilities cl IFRSPrior1YearInstant255987000JPY
Other financial liabilities cl IFRSCurrentQuarterInstant364969000JPY
Income taxes payable cl IFRSPrior1YearInstant1003852000JPY
Income taxes payable cl IFRSCurrentQuarterInstant2643748000JPY
Provisions cl IFRSPrior1YearInstant31583000JPY
Provisions cl IFRSCurrentQuarterInstant23663000JPY
Contract liabilities cl IFRSPrior1YearInstant823011000JPY
Contract liabilities cl IFRSCurrentQuarterInstant898709000JPY
Other current liabilities cl IFRSPrior1YearInstant712834000JPY
Other current liabilities cl IFRSCurrentQuarterInstant567208000JPY
Total current liabilities IFRSPrior1YearInstant8617088000JPY
Total current liabilities IFRSCurrentQuarterInstant10100482000JPY
Borrowings ncl IFRSPrior1YearInstant19634447000JPY
Borrowings ncl IFRSCurrentQuarterInstant18986660000JPY
Other financial liabilities ncl IFRSPrior1YearInstant323160000JPY
Other financial liabilities ncl IFRSCurrentQuarterInstant409820000JPY
Deferred tax liabilities IFRSPrior1YearInstant385837000JPY
Deferred tax liabilities IFRSCurrentQuarterInstant－JPY
Retirement benefit liability ncl IFRSPrior1YearInstant97647000JPY
Retirement benefit liability ncl IFRSCurrentQuarterInstant97870000JPY
Provisions ncl IFRSPrior1YearInstant56120000JPY
Provisions ncl IFRSCurrentQuarterInstant57580000JPY
Non current labilities IFRSPrior1YearInstant20497214000JPY
Non current labilities IFRSCurrentQuarterInstant19551932000JPY
Liabilities IFRSPrior1YearInstant29114303000JPY
Liabilities IFRSCurrentQuarterInstant29652414000JPY
Share capital IFRSPrior1YearInstant3956738000JPY
Share capital IFRSCurrentQuarterInstant3956738000JPY
Capital surplus IFRSPrior1YearInstant4550372000JPY
Capital surplus IFRSCurrentQuarterInstant4558543000JPY
Treasury shares IFRSPrior1YearInstant-1085546000JPY
Treasury shares IFRSCurrentQuarterInstant-1085605000JPY
Retained earnings IFRSPrior1YearInstant27804689000JPY
Retained earnings IFRSCurrentQuarterInstant33501400000JPY
Other components of equity IFRSPrior1YearInstant5123456000JPY
Other components of equity IFRSCurrentQuarterInstant-946349000JPY
Equity attributable to owners of parent IFRSPrior1YearInstant40349709000JPY
Equity attributable to owners of parent IFRSCurrentQuarterInstant39984726000JPY
Equity IFRSPrior1YearInstant40349709000JPY
Equity IFRSCurrentQuarterInstant39984726000JPY
Liabilities and equity IFRSPrior1YearInstant69464013000JPY
Liabilities and equity IFRSCurrentQuarterInstant69637141000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-12-31pass rounding
balance sheet identityconsolidated 2024-03-31pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-03-31pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-03-31pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-03-31pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-03-31pass
statement vs summary · revenueconsolidated 2023-01-01/2023-03-31pass
statement vs summary · revenueconsolidated 2024-01-01/2024-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass
statement vs summary · total assetsconsolidated 2024-03-31pass